Our Pipeline
Target class
Indication
Molecule
Program
Discovery
Preclinical
Phase i/ii
Phase iii
Cytokine
Solid tumors
Skin cancer
Lung cancer
IL-12
ANK-101
Antibody
Solid tumors
Agonist
(Full-length Ab)
Inhibitor
(Nanobody)
ANK-201
ANK-202
ANK-203
Small Molecule
Solid tumors
Agonist
ANK-301
ANK-302
Lead Product Candidate: IL-12 Anchored-Drug Conjugate (ANK-101)
- IL-12 is a cytokine with anti-tumor effects in preclinical and clinical settings
- Systemic IL-12 is highly toxic
ANK-101
- IL-12 bound to the anchor, aluminum hydroxide (Alhydrogel®)
- Retained at the tumor site > 28 days in preclinical models
- Potent single-dosing therapeutic activity as a monotherapy and in combination with other agents in multiple murine tumor models
- Has favorable safety profile (no dose-limiting toxicities) in mice, dogs, and non-human primates